Cinclus Pharma, a clinical-stage biopharma company developing treatments for acid-related diseases, has entered a major licensing and commercialization agreement with European pharmaceutical leader Zentiva. The deal, valued at up to €220 million, grants Zentiva exclusive rights to manufacture and market Cinclus’s lead asset, linaprazan glurate, across the EEA, UK, and Switzerland.
Linaprazan glurate is a next-generation treatment for severe erosive GERD, targeting a European and US market of approximately 10 million patients.
This strategic partnership strengthens Cinclus Pharma’s commercialization pathway in Europe while retaining full rights to the US market, positioning the company for significant global value creation.
Our portfolio company, Purpose Pharma, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Attrogy® (diflunisal). Attrogy® is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
If approved by the European Commission (EC), Attrogy® will become the only oral therapy authorized for treating both stage 1 and stage 2 ATTR polyneuropathy.
This represents a major advancement for hATTR patients, offering a convenient and accessible oral treatment option that addresses a significant unmet need. Attrogy® could enable earlier and more sustained management of disease progression, helping patients maintain their quality of life longer.
About Purpose Pharma
Purpose Pharma is a biopharmaceutical company focused on developing innovative treatments for rare diseases with high unmet medical needs